Seagen Inc. (SGEN) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 Bothell, WA, 美国. 現任CEO為 David R. Epstein.
SGEN 擁有 IPO日期為 2001-03-09, 3,256 名全職員工, 在 NASDAQ Global Select, 市值為 $43.15B.
Seagen Inc. is a biotechnology company headquartered in Bothell, Washington, specializing in the development and commercialization of cancer therapies. The company's commercial portfolio includes ADCETRIS for Hodgkin lymphoma and CD30-positive T-cell lymphomas, PADCEV for advanced urothelial cancer, and TUKYSA for HER2-positive breast cancer, alongside several pipeline candidates such as TIVDAK for cervical cancer and multiple novel antibody-drug conjugates targeting various oncology indications. Seagen operates globally and maintains strategic collaboration agreements with leading pharmaceutical companies including Takeda, Merck, and Genmab. The company was founded in 1997 as Seattle Genetics and rebranded as Seagen Inc. in 2020.
